Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five ...
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral pre...
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal ...
Surface Oncology (NASDAQ:SURF) said it began two phase 2 studies of SRF388 in liver and lung cancers. The company said a phase 2 trial is evaluating SRF388 in combination with Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) atezolizumab and bevacizumab against placebo plus atezolizumab and be...
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer CAMBRIDGE, Ma...
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical and translational dat...
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Surface’s board of directors granted Theresa Bo...
Surface Oncology (NASDAQ:SURF) shares have climbed ~7% pre-market after the immuno-oncology firm achieved the $30M milestone payment with the first patient dosed by GlaxoSmithKline (NYSE:GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors. In late 2020, Surface sig...
Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by GlaxoSmithKline (GSK)...
News, Short Squeeze, Breakout and More Instantly...
Surface Oncology Inc. Company Name:
SURF Stock Symbol:
NASDAQ Market:
Surface Oncology Inc. Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Surface Oncology Inc. (SURF) is expected to report $-0.36 for Q3 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Serv...